{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:17:09Z","timestamp":1791685029872,"version":"4.3.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:p>Rituximab is frequently used to treat B-cell lymphomas. The major adverse effect of rituximab is infusion-related reaction (IRR). The standard of care for IRR is not well established. We explored the incidence, risk factors, and impact on outcome of IRR in our institution. In total, 254 patients with B-cell lymphomas diagnosed from January 2016 to March 2018 were retrospectively reviewed. The median age was 61 (range 18\u201391). Diffuse large B-cell lymphoma (DLBCL) (71.3%) was the most common subtype of lymphomas. IRR occurred in 55 patients (21.7%). Incidence of IRR was significantly higher for follicular lymphoma (46.4%) than DLBCL (18.8%). Fifty patients (19.7%) experienced IRR at the first treatment cycle. Six of them had another IRR in subsequent treatment. Five patients had IRR\u2005\u2265\u2005grade 3. Two patients did not complete the treatment courses due to IRR. Rituximab-associated IRR is manageable by a slower infusion rate and administration of steroids and antihistamines. Patients experiencing IRR should not be excluded from subsequent rituximab treatment. Incidence of IRR is higher in follicular lymphoma than DLBCL. IRR is not predicted by any risk factors and do not affect the clinical outcome of patients with B-cell lymphomas.<\/jats:p>","DOI":"10.1097\/md.0000000000042972","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:01:23Z","timestamp":1751295683000},"page":"e42972","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors and clinical consequences of rituximab infusion-related reactions"],"prefix":"10.1097","volume":"104","author":[{"given":"Chi-Hsiang","family":"Hou","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Center of Hemophilia and Coagulation Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Nursing Department, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-0304","authenticated-orcid":false,"given":"Hung","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Center of Hemophilia and Coagulation Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Department of Medicine, School of Medicine, Chang Gung University, Taoyuan City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen-Chin","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Center of Hemophilia and Coagulation Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Department of Medicine, School of Medicine, Chang Gung University, Taoyuan City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Wen","family":"Kao","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Lan","family":"Lee","sequence":"additional","affiliation":[{"name":"Nursing Department, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260813","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-hodgkin lymphoma.","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pop.2016.07.012","article-title":"Lymphoma.","volume":"43","author":"Mugnaini","year":"2016","journal-title":"Prim Care"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014the world\u2019s first oncology monoclonal antibody therapy.","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"R5-20260813","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience.","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"R6-20260813","first-page":"148","article-title":"Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma.","volume":"35","author":"Dotan","year":"2010","journal-title":"PT"},{"key":"R7-20260813","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion"},{"key":"R9-20260813","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"R10-20260813","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R11-20260813","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/eci.11.75","article-title":"Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies.","volume":"8","author":"Hong","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"R12-20260813","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera\u00ae).","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R13-20260813","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jaip.2017.08.004","article-title":"Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms.","volume":"5","author":"Wong","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R14-20260813","first-page":"451","article-title":"Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer\u2013identification, prevention, and management.","volume":"5","author":"Kang","year":"2007","journal-title":"J Support Oncol"},{"key":"R17-20260813","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"R18-20260813","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","article-title":"Reactions to rituximab in an outpatient infusion center: a 5-year review.","volume":"5","author":"Levin","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R19-20260813","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clim.2016.08.011","article-title":"Anti-CD20 antibody treatment of non-Hodgkin lymphomas.","volume":"172","author":"Engelhard","year":"2016","journal-title":"Clin Immunol"},{"key":"R20-20260813","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus\u2010associated immune cytopenias: a multicenter retrospective cohort study of 71 adults.","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"R21-20260813","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00296-019-04272-1","article-title":"Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases.","volume":"39","author":"Vikse","year":"2019","journal-title":"Rheumatol Int"},{"key":"R22-20260813","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14397595.2015.1060665","article-title":"Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"R24-20260813","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"R25-20260813","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors.","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R26-20260813","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse reactions to biologic therapy.","volume":"37","author":"Patel","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"R27-20260813","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.","volume":"124","author":"Brennan","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R28-20260813","first-page":"524507","article-title":"Successful desensitization of a patient with rituximab hypersensitivity.","volume":"2015","author":"Ataca","year":"2015","journal-title":"Case Rep Immunol"},{"key":"R29-20260813","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"R30-20260813","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R31-20260813","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R32-20260813","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R33-20260813","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12185-010-0583-z","article-title":"A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center.","volume":"91","author":"Chiang","year":"2010","journal-title":"Int J Hematol"},{"key":"R34-20260813","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40259-021-00487-6","article-title":"Factors influencing infusion-related reactions following dosing of reference Rituximab and PF-05280586, a Rituximab Biosimilar.","volume":"35","author":"Courville","year":"2021","journal-title":"BioDrugs"},{"key":"R35-20260813","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1746-1596-6-33","article-title":"The predictive significance of CD20 expression in B-cell lymphomas.","volume":"6","author":"Prevodnik","year":"2011","journal-title":"Diagn Pathol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:04:30Z","timestamp":1786633470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":31,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042972","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}